Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | S100B | P04271 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416782 | 0.98 | ALDH1A1 (0.65) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 | |
| Sulfamide SCHEMBL2421696 | 0.92 | KDM4E (0.58) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 | |
| SCHEMBL9513713 | 0.83 | KDM4E (0.68) | ALDH1A1KDM4EL3MBTL1KEAP1TDP1 | |
| SCHEMBL11613977 | 0.83 | ADRA2C (0.62) | ALDH1A1KDM4EL3MBTL1HPGDHSD17B10 | |
| SCHEMBL1871089 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 | |
| SCHEMBL573134 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 | |
| SCHEMBL22964428 | 0.82 | KDM4E (0.46) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 | |
| SCHEMBL1878340 | 0.80 | ALDH1A1 (0.69) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 | |
| SCHEMBL3381896 | 0.80 | GAA (0.44) | ALDH1A1KDM4EL3MBTL1HPGDHSD17B10 | |
| SCHEMBL1154557 | 0.79 | KDM4E (0.71) | ALDH1A1KDM4EL3MBTL1KEAP1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415760-A2 | CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2415760-A2 | CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-7319111-B2 | Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319111-B2 | Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319111-B2 | Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1610753-A4 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1610753-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-0133234-A2 | Imidazoquinazolin-2-one compounds process for their production and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-02-20 | — | — | EP | disclosed |
| US-4209528-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-4137325-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-01-30 | — | — | US | disclosed |
| US-4129735-A | MULTISTAGE FROM AN OXAMIC ACID ESTER AND PHOSPHORUS PENTACHLORIDE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-12-12 | — | — | US | disclosed |
| US-4123432-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-10-31 | — | — | US | disclosed |
| US-4116960-A | ANTI-ALLERGIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4087606-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-05-02 | — | — | US | disclosed |
| US-4057632-A | ANTIBODY-ANTIGEN INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-11-08 | — | — | US | disclosed |
| US-4054591-A | ANTIALLERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4013647-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | ALDH1A1 3281/4885KDM4E 4540/4885L3MBTL1 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.